ACE2 and COVID-19: Other reviews also highlighted changes in liver enzymes and bilirubin in patients with COVID-19, noting that these manifestations could be multifactorial, including medications, previous liver disease, and even direct viral injury (7, 8), since hepatocytes also have the angiotensin-converting enzyme 2 (ACE2), which the virus binds to enter human cells (15).